LINC-ROR and neoplasm: Indeed, ROR inhibitors cooperate with statins to kill TNBC (triple-negative breast cancer) cells, and in addition, ROR-selective antagonists are very effective manifested by leading tumor regression and blocking metastasis in multiple TNBC models (Cai et al., 2019).